Biogen is a global biotechnology leader in neurological disease and one of the world's leading biotechnology companies.
Biogen generated $9.9 billion in revenue in 2025, growing approximately 2% year-over-year, with its commercial trajectory shaped by the launch of LEQEMBI (lecanemab) — the first disease-modifying therapy for Alzheimer's disease — alongside continued revenue from its multiple sclerosis franchise. LEQEMBI achieved nearly $1 billion in global in-market sales in 2025, representing strong uptake in the United States and initial launch progress in Japan and other markets. Biogen's Fit for Growth restructuring program is generating approximately $1 billion in annual gross savings to fund investment in the Alzheimer's franchise, rare disease pipeline, and immunology programs. The company's partnership with Samsung Bioepis provides a significant biosimilar revenue stream.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Technological Know-How and Key Products
7. M&A and Partnerships
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Biogen — Key Financial Metrics 2023-2025
Table 2. Biogen — Revenue by Product 2023-2025
Table 3. Biogen — Revenue by Geography 2023-2025
Table 4. Biogen — R&D Investment 2023-2025
Table 5. Biogen — SWOT Analysis
Table 6. Biogen — Key Products and Pipeline 2025
Table 7. Biogen — M&A Activity 2020-2025
Table 8. Biogen — Key Management 2025
Table 9. Biogen — Strategic Priorities 2025-2030
